摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl (S)-4-benzyl-2-(2-oxoethyl)piperazine-1-carboxylate | 477220-35-2

中文名称
——
中文别名
——
英文名称
tert-butyl (S)-4-benzyl-2-(2-oxoethyl)piperazine-1-carboxylate
英文别名
(S)-4-benzyl-2-(2-oxo-ethyl)-piperazine-1-carboxylic acid tert-butyl ester;Tert-butyl (S)-4-benzyl-2-(2-oxoethyl)piperazine-1-carboxylate;tert-butyl (2S)-4-benzyl-2-(2-oxoethyl)piperazine-1-carboxylate
tert-butyl (S)-4-benzyl-2-(2-oxoethyl)piperazine-1-carboxylate化学式
CAS
477220-35-2
化学式
C18H26N2O3
mdl
——
分子量
318.416
InChiKey
JDLGPEFVTLRBOQ-INIZCTEOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    425.0±35.0 °C(Predicted)
  • 密度:
    1.101±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    23
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    49.8
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    tert-butyl (S)-4-benzyl-2-(2-oxoethyl)piperazine-1-carboxylate 在 10 wt% Pd(OH)2 on carbon 、 氢气 、 sodium hydride 、 N,N-二异丙基乙胺三氟乙酸 作用下, 以 四氢呋喃1,4-二氧六环甲醇二氯甲烷 、 mineral oil 为溶剂, 反应 57.75h, 生成 4-((S)-3-((1H-imidazol-2-yl)methyl)piperazin-1-yl)-6-(2,3-dihydro1H-inden-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine
    参考文献:
    名称:
    [EN] PYRROLIDINE-FUSED HETEROCYCLES
    [FR] HÉTÉROCYCLES FUSIONNÉS À LA PYRROLIDINE
    摘要:
    提供了Formula (I)的化合物:其中变量在此处定义。
    公开号:
    WO2021173923A1
  • 作为产物:
    描述:
    (S)-4-苄基-2-(2-羟基乙基)哌嗪-1-羧酸叔丁酯草酰氯二甲基亚砜三乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 1.17h, 以50%的产率得到tert-butyl (S)-4-benzyl-2-(2-oxoethyl)piperazine-1-carboxylate
    参考文献:
    名称:
    [EN] PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS
    [FR] ARYLES BENZODIAZEPINES A SUBSTITUTION DE PIPERAZINE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DE RECEPTEUR DE DOPAMINE DANS LE TRAITEMENT DE TROUBLES PSYCHOTIQUES
    摘要:
    本文描述了公式(I)的抗精神药物化合物,其中,A是一个可选的苯并嵌有零至三个异原子(N、O和S)的五元或六元芳香环;Alk是(C1-4)烷基烯,可选地取代为OH、甲氧基、乙氧基或F;Ar是可选取代的苯基、萘基、单环杂芳基或双环杂芳基;R1是氢或(C1-4)烷基,可选地取代为OH、OR3或OCH2CH2OH,其中R3是(C1-2)烷基;R2是H、(C1-6)烷基、卤素、氟代(C1-6)烷基、OR4、SR4、NO2、CN、COR4、CONR5R6、SO2NR5R6、NR5R6、NR5COR4、NR5SO2R4或可选取代的苯基,其中R4是氢、(C1-6)烷基、氟代(C1-6)烷基、苄基或可选取代的苯基,R5和R6独立地是氢、(C1-6)烷基或可选取代的苯基;Z是一个或两个取代基,独立地选自氢、卤素、(C1-6)烷基、氟代(C1-6)烷基、OR7、SR7、NO2、CN、COR7、CONR8R9、SO2NR8R9、NR8SO2R7、NR8R9或可选取代的苯基,其中R7是氢、(C1-6)烷基、氟代(C1-6)烷基、苄基或可选取代的苯基,R8和R9独立地是氢、(C1-6)烷基或可选取代的苯基;以及其盐、溶剂合物和晶型。还描述了将公式(I)的化合物用作多巴胺D2受体拮抗剂和治疗精神病和双相障碍的药物,以及公式(I)的化合物的制剂。还描述了作为公式(I)化合物合成的中间体有用的化合物。
    公开号:
    WO2003082877A1
点击查看最新优质反应信息

文献信息

  • Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
    申请人:Hutchison Alan
    公开号:US20050182068A1
    公开(公告)日:2005-08-18
    Melanin concentrating hormone receptor ligands (especially 1-benzyl-4-aryl-piperazines, 1-benzyl-4-aryl-piperidines and related compounds), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e.g., receptor localization studies).
    提供了黑色素浓集激素受体配体(尤其是1-苄基-4-芳基哌嗪,1-苄基-4-芳基哌啶和相关化合物),能够调节MCH受体活性。这样的配体可用于调节体内或体外MCH结合到MCH受体,并且在人类、家养伴侣动物和家畜动物的多种代谢、进食和性疾病治疗中特别有用。提供了用于治疗此类疾病的制药组合物和方法,以及用于检测MCH受体的配体的方法(例如受体定位研究)。
  • Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
    申请人:Aicher Daniel Thomas
    公开号:US20050203296A1
    公开(公告)日:2005-09-15
    Described herein are antipyschotic compounds of formula (I) wherein, A is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, O, and S; Alk is (C 1-4 ) alkylene optionally substituted with OH, methoxy, ethoxy, or F; Ar is optionally substituted phenyl, naphthyl, monocyclic heteroaromatic, or bicyclic heteroaromatic; R 1 is hydrogen or (C 1-4 ) alkyl optionally substituted with OH, OR 3 , or OCH 2 CH 2 OH, wherein R 3 is (C 1-2 ) alkyl; R 2 is H, (C 1-6 ) alkyl, halogen, fluorinated (C 1-6 ) alkyl, OR 4 , SR 4 , NO 2 , CN, COR 4 , CONR 5 R 6 , SO 2 NR 5 R 6 , NR 5 R 6 , NR 5 COR 4 , NR 5 SO 2 R 4 , or optionally substituted phenyl, wherein R 4 is hydrogen, (C 1-6 ) alkyl, fluorinated (C 1-6 ) alkyl, benzyl, or optionally substituted phenyl, R 5 and R 6 are independently hydrogen, (C 1-6 ) alkyl, or optionally substituted phenyl; Z is one or two substituents independently selected from hydrogen, halogen, (C 1-6 ) alkyl, fluorinated (C 1-6 ) alkyl, OR 7 , SR 7 , NO 2 , CN, COR 7 , CONR 8 R 9 , SO 2 NR 8 R 9 , NR 8 SO 2 R 7 , NR 8 R 9 , or optionally substituted phenyl, wherein R 7 is hydrogen, (C 1-6 ) alkyl, fluorinated alkyl, benzyl, or optionally substituted phenyl, R 8 and R 9 are independently hydrogen, (C 1-6 ) alkyl, or optionally substituted phenyl; and salts, solvates, and crystal forms thereof. Also described are the use of the compounds of formula (a) as antagonists of the dopamine D 2 receptor and as agents for the treatment of psychosis and bipolar disorders, and pharmaceutical formulations of the compounds of formula (I). Also described are compounds useful as intermediates for the synthesis of the compounds of formula (I).
    本文描述了式(I)的抗精神病化合物,其中A是一个选择性地与N、O和S中的零到三个杂原子独立选定的五元或六元芳香环,可以与苯并联;Alk是(C1-4)的烷基,可以选择性地用OH,甲氧基,乙氧基或F取代;Ar是选择性取代的苯基,萘基,单环杂芳基或双环杂芳基;R1是氢或(C1-4)烷基,可以选择性地用OH,OR3或OCH2CH2OH取代,其中R3是(C1-2)烷基;R2是H,(C1-6)烷基,卤素,氟化的(C1-6)烷基,OR4,SR4,NO2,CN,COR4,CONR5R6,SO2NR5R6,NR5R6,NR5COR4,NR5SO2R4或选择性取代的苯基,其中R4是氢,(C1-6)烷基,氟化的(C1-6)烷基,苄基或选择性取代的苯基,R5和R6独立地是氢,(C1-6)烷基或选择性取代的苯基;Z是一个或两个取代基,独立选择自氢,卤素,(C1-6)烷基,氟化的(C1-6)烷基,OR7,SR7,NO2,CN,COR7,CONR8R9,SO2NR8R9,NR8SO2R7,NR8R9或选择性取代的苯基,其中R7是氢,(C1-6)烷基,氟化的烷基,苄基或选择性取代的苯基,R8和R9独立地是氢,(C1-6)烷基或选择性取代的苯基;以及其盐,溶剂化合物和晶体形式。本文还描述了将式(a)的化合物用作多巴胺D2受体的拮抗剂以及用于治疗精神病和双相障碍的药物,以及式(I)的化合物的制药配方。还描述了用于合成式(I)的化合物的中间体。
  • MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES
    申请人:Hutchison Alan
    公开号:US20050065162A1
    公开(公告)日:2005-03-24
    Melanin concentrating hormone receptor ligands (especially 1-benzyl-4-aryl-piperazines, 1-benzyl-4-aryl-piperidines and related compounds), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e.g., receptor localization studies).
    提供了黑色素浓集激素受体配体(尤其是1-苄基-4-芳基哌嗪、1-苄基-4-芳基哌啶和相关化合物),能够调节MCH受体活性。这样的配体可以用于调节体内或体外MCH结合到MCH受体,并且特别适用于治疗人类、家畜伴侣动物和家畜动物的各种代谢、饮食和性功能障碍。提供了用于治疗此类障碍的药物组合物和方法,以及用于检测MCH受体的配体的使用方法(例如,受体定位研究)。
  • MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF
    申请人:Wang Ying
    公开号:US20110130382A1
    公开(公告)日:2011-06-02
    The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2-a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X 1 , X 2 , X 3 , X 4 , Y 1 , Y 2 , and Y 3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.
    本申请涉及以下化合物的衍生物:1,2,3,4,4a,5,6,7-八氢吡嗪并[1,2-a][1,4]苯二氮平、1,2,3,4,4a,5,6,7-八氢吡嗪并[1,2-a][1,5]苯二氮平、2,3,4,4a,5,6,7,11b-八氢-1H-吡啶[3,4-d][2]苯并氮平、1,2,3,4,4a,5,6,7-八氢吡嗪并[1,2-a][1]苯并氮平、1,2,3,4,4a,5-六氢-7H-吡嗪并[1,2-a][4,1]苯并噁唑平和2,3,4,4a,5,6-六氢-1H-吡嗪并[2,1-d][1,5]苯并噁唑平,以及式(I)中R1、R2、R3、R4、R5、R6、X1、X2、X3、X4、Y1、Y2和Y3的衍生物。本申请还涉及包含这些化合物的组合物,以及使用这些化合物和组合物治疗疾病的方法,以及鉴定这些化合物的方法。
  • Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues.
    申请人:NEUROGEN CORPORATION
    公开号:EP1935885A2
    公开(公告)日:2008-06-25
    Melanin concentrating hormone receptor ligands (especially 1-benzyl-4-arylpiperazines, 1-benzyl-4-aryl-piperidines and related compounds), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e.g., receptor localization studies).
    提供了能够调节 MCH 受体活性的黑色素浓缩激素受体配体(特别是 1-苄基-4-芳基哌嗪、1-苄基-4-芳基哌啶及相关化合物)。此类配体可用于调节体内或体外 MCH 与 MCH 受体的结合,特别适用于治疗人类、驯养的伴侣动物和家畜的各种代谢、喂养和性功能紊乱。本文提供了治疗此类疾病的药物组合物和方法,以及使用此类配体检测 MCH 受体(如受体定位研究)的方法。
查看更多